QUAY STEVEN C 4

What Happened
Steven C. Quay, President & CEO and a director of Atossa Therapeutics (ATOS), received a grant of 65,000 restricted stock units (RSUs) on March 27, 2026. The RSUs were granted at $0.00 (no cash paid at grant) and thus have no immediate purchase value recorded on the Form 4. Each RSU represents a contingent right to receive one share of common stock upon vesting.

Key Details

• Transaction date: 2026-03-27; grant type: Award/Grant (RSUs); reported grant amount: 65,000 RSUs; reported price: $0.00 (total reported cash value = $0).
• Vesting: RSUs vest in three equal annual installments on the first three anniversaries of March 26, 2026 (per footnote).
• Reverse split adjustment: Reported share amounts have been adjusted for the 1-for-15 reverse stock split effective Feb 2, 2026 (per footnote).
• Ownership after transaction: Not specified in the provided summary of the Form 4.
• Filing: Form 4 filed 2026-03-31 (appears to be within the SEC two-business-day filing window for a 3/27 transaction).
• Other note: Footnote indicates Ensisheim Partners, LLC is partly owned by the reporting person and Dr. Shu-Chih Chen; the reporting person disclaims beneficial ownership of certain securities except for any pecuniary interest.

Context
This was an equity award (RSUs), not an open-market purchase or sale. RSUs are contingent and only convert to shares if/when they vest, so they do not represent immediate share purchases or sales. For retail investors, awards signal company compensation decisions but do not, by themselves, indicate the insider is buying stock on the open market.